NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

LOS ANGELES, CA / ACCESS Newswire / February 4, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...

To teach your children about investing, put your money where your mouth is with this fun and potentially profitable exercise.

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

Novo Holdings, the primary shareholder of Novo Nordisk, is targeting a doubling of size for its recent acquisition, Catalent, within five years. This move comes as the firm anticipates an increased ...

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NYSE:NVO), hopes to double the size of its recently acquired contract drugmaker Catalent (NYSE:CTLT) over five years ...

(Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk, hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the ...

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...